A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
BioCryst Pharmaceuticals (BCRX) just hit an inflection point, reporting its first full year of net income on the back of higher revenue, expanding operating profit and stronger uptake of hereditary angioedema treatment ORLADEYO. See our latest analysis for BioCryst Pharmaceuticals. The strong earnings surprise, first full year of net income and the Astria Therapeutics acquisition have gone hand in hand with powerful momentum, with a 1 month share price return of 32.98% and a 90 day gain of 22.21%. However, the 1 year total shareholder return of 2.46% and 5 year total shareholder return of 21.14% highlight how recent optimism follows a weaker long term record. If BioCryst's rare disease story has caught your attention, you may also want to see how other specialist drug developers are priced and performing through our 28 healthcare AI stocks With BioCryst now profitable, growing revenue and trading at US$8.75 alongside a value score of 5, is the recent share price jump just a c
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BioCryst's First Profitable Year Recasts Hereditary Angioedema Growth Story [Yahoo! Finance]Yahoo! Finance
- BioCryst (BCRX) Soars 10.8% on Swing to Profits [Yahoo! Finance]Yahoo! Finance
- Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? [Yahoo! Finance]Yahoo! Finance
BCRX
Earnings
- 2/26/26 - Beat
BCRX
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- BCRX's page on the SEC website